Focus on Lymphoma & Myeloma (Volume 4, Issue 4.1)

Focus on Lymphoma & Myeloma

Volume 4, Issue 4.1

This supplement features a look at controversies in myeloma treatment, the future of immunotherapy for lymphoma, newly approved and investigational therapies, and more.

Table of Contents

Newly Approved Drugs

The Year in FDA Approvals

Thursday, March 1st, 2018
In 2017, the U.S. Food and Drug Administration (FDA) approved several therapies for the treatment of lymphoid malignancies, including the first two chimeric antigen...

In the Pipeline

The Lymphoid Malignancies Pipeline

Thursday, March 1st, 2018
Below is a list of agents under investigation for the treatment of lymphoid malignancies. Information was gathered from ClinicalTrials.gov, as well as the respective...

Features

Controversies in Myeloma: The Who, When, and Why of Treatment

Thursday, March 1st, 2018
The recent expansion of treatment options for patients with multiple myeloma (MM) has introduced new opportunities for redefining the goals of therapy. At the...

Immunotherapy: Exploring the Next Frontier for Non-Hodgkin Lymphoma Treatment

Thursday, March 1st, 2018
When the U.S. Food and Drug Administration approved the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel for the treatment of relapsed or refractory...

Meeting News

A Curative Strategy for High-Risk Smoldering Multiple Myeloma?

Thursday, March 1st, 2018
In a phase II trial of patients with previously untreated smoldering multiple myeloma (SMM), the combination of carfilzomib, lenalidomide, and dexamethasone, followed by autologous...

Final Analysis of IFM2009 Trial Confirms Predictive Value of Minimal Residual Disease in Myeloma

Thursday, March 1st, 2018
Because survival for patients with multiple myeloma (MM) has significantly improved within the past decade, complete response (CR) rates may no longer be a...

Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory...

Thursday, March 1st, 2018
According to final results from the phase III ASPIRE study assessing patients with relapsed/refractory multiple myeloma (MM), adding the proteasome inhibitor carfilzomib to a...

Doubling Down on Double Transplant for Myeloma: Updated Results from EMN02/H095

Thursday, March 1st, 2018
More than a year ago, at the 2016 ASH Annual Meeting, Michele Cavo, MD, from the Serágnoli Institute of Hematology at Bologna University School...

BCMA Antibody Drug Conjugate Active in Patients With Heavily Pretreated Myeloma

Thursday, March 1st, 2018
In a phase I study presented at the 2017 ASH Annual Meeting, 60 percent of patients with heavily-pretreated multiple myeloma (MM) responded to treatment...

Early-Phase Study Finds Venetoclax Plus Obinutuzumab Safe and Effective in Patients with Untreated CLL

Thursday, March 1st, 2018
Venetoclax – a highly selective, potent BCL2 inhibitor – demonstrated significant anti-tumor activity in patients with chronic lymphocytic leukemia (CLL), both as monotherapy and...

For Patients With Plasma Cell Disorders, Are Two Flu Vaccines Better Than One?

Thursday, March 1st, 2018
Patients with plasma cell disorders (PCDs) such as multiple myeloma (MM) have compromised immunity, and potent anti-cancer treatments further deplete immunity, making them highly...

Brentuximab Vedotin Plus R-CHP a Frontline Treatment Option for Patients with NHL Subtypes

Thursday, March 1st, 2018
The CD30-directed immunoconjugate brentuximab vedotin has demonstrated efficacy in Hodgkin lymphoma (HL) and other T-cell lymphomas. According to research presented at the 2017 ASH...

Addition of Rituximab to High-Dose Chemotherapy Does Not Improve Response in Patients With Central...

Thursday, March 1st, 2018
According to results of an international, randomized, phase III trial, combining rituximab with high-dose, methotrexate-based chemotherapy did not improve response rates or survival for...

Daratumumab Shows Efficacy in Previously Treated Systemic Light-Chain Amyloidosis

Thursday, March 1st, 2018
Daratumumab, an anti-CD38 monoclonal antibody indicated for the treatment of patients with multiple myeloma (MM), has also shown efficacy in patients with systemic light-chain...

CC-122 Plus Obinutuzumab: An Effective, Chemotherapy-Free Regimen for Non-Hodgkin Lymphoma?

Thursday, March 1st, 2018
Results from a phase Ib study of CC-122 (an oral agent that binds the cereblon ubiquitin ligase complex), in combination with obinutuzumab, showed positive...

A New BTK Inhibitor on the Block: Zanubrutinib Demonstrates High Activity in Aggressive Non-Hodgkin...

Thursday, March 1st, 2018
Zanubrutinib (BGB-3111) is a potent, highly specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor that is effective in treating aggressive B-cell malignancies, according to...

SHARE